Psoriasis Registry Reaches Milestone, Enrolls its 3,000th patient

Single Registry Analyzing Various Treatment Options Benefits Researchers, Health Care Providers and Patients 

Portland, Ore. (June 26, 2017)—Since its launch two years ago, the Corrona Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, the leading sponsor of registries in autoimmune and immune-mediated diseases, has enrolled its 3,000th patient. 

Designed to study the comparative safety and effectiveness of psoriasis treatments, the Corrona Psoriasis Registry’s 3,000 psoriasis patients come from 128 sites across 33 states.

More than 230 participating dermatology health care providers have contributed data to the registry. Additionally, data from the registry has contributed to 18 research posters that have been presented at medical conferences across the country analyzing disease severity, concurrent medical conditions, and patient reported outcomes.

“The data collected in the Corrona Registry is critical in helping scientists advance research that could demonstrate the most effective and safest treatment strategies available for all psoriatic disease patients,” said Randy Beranek, National Psoriasis Foundation president and CEO. “We are encouraged by the enrollment numbers and expect as more patients and health care providers learn the positive impact the registry has on patient research, it will continue to increase.”

In a fundamental paradigm shift from the traditional model where each individual pharmaceutical company sponsors its own Phase 4 clinical study to investigate the post-approval safety of its drug, the Corrona Psoriasis Registry uses a collaborative model which integrates the post-approval safety study (PASS) commitments of multiple companies into a single, large-scale registry with multiple drug treatment cohorts. This collaborative model offers numerous advantages, including streamlining the workflow for investigators and patients into a single protocol and set of patient questionnaires. The Corrona collaborative model has been designated to support FDA post-approval safety commitments for two recently approved IL-17 inhibitor biologics for psoriasis.

“As an independent registry, the Corrona Registry is well positioned to answer critical research questions facing psoriasis patients on the risk-benefit profile of newly approved drugs, empowering the psoriasis patient community,” said Dr. Mark Lebwohl, professor and chairman, Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, chairman emeritus of the NPF Medical Board, and scientific co-director of the registry.

“We greatly appreciate the contributions of participating dermatologists and their patients for enriching the knowledge base accessible to the broader psoriasis community,” said Dr. Jeff Greenberg, chief scientific officer of Corrona.  

The Corrona Psoriasis Registry is the largest, independent U.S. registry of psoriasis patients. The registry was launched as a commitment to the psoriasis community to help researchers compare the safety and effectiveness of FDA-approved psoriasis therapies.

Psoriasis is a chronic, immune-mediated disease that causes raised, red, scaly patches to appear on the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis is not contagious. More than 8 million Americans have psoriasis.

Learn more about the Corrona Psoriasis Registry, visit


About the National Psoriasis Foundation

Serving its community through more than 50 years of patient support, advocacy, research funding, and education, the National Psoriasis Foundation (NPF) is the world’s leading nonprofit fighting for individuals with psoriasis and psoriatic arthritis. The NPF mission is to drive efforts to cure psoriatic disease and dramatically improve the lives of more than 8 million Americans affected by this chronic immune-mediated disease. As part of that effort, NPF created its Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. To date, NPF has funded more than $21 million in research grants and fellowships that help drive discoveries that may lead to more and better treatments and ultimately a cure. Learn more at